CYTOSORBENTS CORPORATION Financials Cytosorbents Corporation
Equities
CTSO
US23283X2062
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.819 USD | +1.24% |
|
+2.12% | -26.22% |
| Mar. 15 | Cytosorbents Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 14 | Earnings Flash (CTSO) CYTOSORBENTS Reports Q4 Revenue $8.7M, vs. Street Est of $9.8M | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 124.8 | 344.1 | 182.2 | 67.64 | 57.95 | 44.48 | - | - |
| Enterprise Value (EV) 1 | 124.8 | 344.1 | 182.2 | 67.64 | 57.95 | 44.48 | 44.48 | 44.48 |
| P/E ratio | -6.42 x | -39.9 x | -7.35 x | -2.07 x | -1.73 x | -2.28 x | -4.03 x | -5.46 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 5 x | 8.39 x | 4.22 x | 1.95 x | 1.59 x | 1.1 x | 0.93 x | 0.85 x |
| EV / Revenue | 5 x | 8.39 x | 4.22 x | 1.95 x | 1.59 x | 1.1 x | 0.93 x | 0.85 x |
| EV / EBITDA | -7.46 x | -68.8 x | -11.5 x | -2.52 x | -2.23 x | -2.63 x | -5.12 x | - |
| EV / FCF | -6,829,267 x | -54,433,348 x | - | - | -2,611,374 x | - | - | - |
| FCF Yield | -0% | -0% | - | - | -0% | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 32,424 | 43,176 | 43,476 | 43,636 | 52,212 | 54,306 | - | - |
| Reference price 2 | 3.850 | 7.970 | 4.190 | 1.550 | 1.110 | 0.8190 | 0.8190 | 0.8190 |
| Announcement Date | 3/5/20 | 3/9/21 | 3/8/22 | 3/9/23 | 3/14/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 24.95 | 41 | 43.17 | 34.69 | 36.35 | 40.31 | 47.76 | 52.34 |
| EBITDA 1 | -16.73 | -5.002 | -15.81 | -26.84 | -26.05 | -16.9 | -8.691 | - |
| EBIT 1 | -18.97 | -10.37 | -22.74 | -31.52 | -31.21 | -20.96 | -9.119 | -7.456 |
| Operating Margin | -76.05% | -25.29% | -52.69% | -90.87% | -85.86% | -52% | -19.09% | -14.24% |
| Earnings before Tax (EBT) 1 | -20.36 | -8.964 | -25.3 | -33.9 | -29.32 | -20.83 | -9.17 | -7.456 |
| Net income 1 | -19.27 | -7.837 | -24.56 | -32.81 | -28.51 | -20.64 | -9.015 | -7.456 |
| Net margin | -77.22% | -19.11% | -56.89% | -94.59% | -78.43% | -51.2% | -18.88% | -14.24% |
| EPS 2 | -0.6000 | -0.2000 | -0.5700 | -0.7500 | -0.6400 | -0.3600 | -0.2033 | -0.1500 |
| Free Cash Flow | -18.28 | -6.322 | - | - | -22.19 | - | - | - |
| FCF margin | -73.26% | -15.42% | - | - | -61.06% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/5/20 | 3/9/21 | 3/8/22 | 3/9/23 | 3/14/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 9.76 | 10.78 | 8.692 | 8.496 | 8.111 | 9.391 | 9.449 | 9.421 | 8.811 | 8.668 | 9.785 | 9.846 | 10.07 | 10.59 |
| EBITDA 1 | -3.811 | -8.242 | - | - | - | -5.037 | - | - | -5.476 | -7.893 | -5.492 | -4.399 | -2.93 | -3.305 |
| EBIT 1 | -5.406 | -9.561 | -7.791 | -8.357 | -9.017 | -6.356 | -7.892 | -6.559 | -7.35 | -9.341 | -7.189 | -5.061 | -4.963 | -4.983 |
| Operating Margin | -55.39% | -88.68% | -89.63% | -98.37% | -111.17% | -67.69% | -83.52% | -69.62% | -83.42% | -107.76% | -73.47% | -51.4% | -49.3% | -47.04% |
| Earnings before Tax (EBT) 1 | -6.406 | -10.04 | -8.966 | -10.88 | -12.2 | -1.859 | -7.326 | -6.153 | -9.193 | -6.648 | -7.117 | -4.99 | -4.892 | -4.913 |
| Net income 1 | -6.406 | -9.307 | -8.966 | -10.88 | -12.2 | -0.767 | -7.326 | -6.153 | -9.193 | -5.834 | -7.117 | -4.99 | -4.892 | -4.913 |
| Net margin | -65.64% | -86.32% | -103.15% | -128.06% | -150.43% | -8.17% | -77.53% | -65.31% | -104.34% | -67.31% | -72.74% | -50.68% | -48.6% | -46.38% |
| EPS 2 | -0.1500 | -0.2100 | -0.2100 | -0.2500 | -0.2800 | -0.0100 | -0.1700 | -0.1400 | -0.2100 | -0.1200 | -0.1200 | -0.0967 | -0.0800 | -0.0633 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 3/8/22 | 5/3/22 | 8/2/22 | 11/3/22 | 3/9/23 | 5/2/23 | 8/1/23 | 11/9/23 | 3/14/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | -18.3 | -6.32 | - | - | -22.2 | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | 0.71 | - | 6.09 | 0.54 | - | - | - |
| Capex / Sales | - | 1.73% | - | 17.55% | 1.48% | - | - | - |
| Announcement Date | 3/5/20 | 3/9/21 | 3/8/22 | 3/9/23 | 3/14/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.819
USD
Average target price
2.667
USD
Spread / Average Target
+225.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.22% | 44.48M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B | |
| +26.76% | 32.03B |
- Stock Market
- Equities
- CTSO Stock
- Financials Cytosorbents Corporation
